Management of thrombocytopenia in a patient with a mechanical mitral valve undergoing autologous hematopoietic stem cell transplantation: case report and review of literature.

Gregory Miller, Samuel B Reynolds, William W Tse

Open access · greenAbstract readCase Reports

In one paragraph

Article in American journal of blood research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact, top 94% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

Anticoagulants in hematologic malignancies: what is the data?Hematology. American Society of Hematology. Education Program · 2025
Review

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Gregory MillerDepartment of Internal Medicine Residency Program, University of Louisville School of Medicine Louisville, Kentucky, The United States.

Samuel B ReynoldsDepartment of Internal Medicine Residency Program, University of Louisville School of Medicine Louisville, Kentucky, The United States.

William W TseDivision of Blood and Marrow Transplantation, FACP, University of Louisville School of Medicine Louisville, Kentucky, The United States.

University of Louisville · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mechanical mitral valves require life-long anticoagulation with Vitamin K Antagonists (VKA), targeted to an international normalized ratio (INR) of 2.5-3.5. While complications, including valve thrombosis and bleeding, are well known, there is a paucity of data on the management of mechanical mitral valves in patients with thrombocytopenia. Due to an increased bleeding risk, the presence of a mechanical mitral valve is considered by some providers as an exclusion criterion for autologous hematopoietic stem-cell transplantation (HSCT). Presented here is a case of a patient with multiple myeloma who successfully underwent autologous HSCT with simultaneous alterations in VKA therapy for continued anticoagulation in the setting of an underlying mechanical mitral valve.

Indexed as

Anticoagulationautologousmitralthrombocytopeniavalve

Identifiers

PMID32206441

PMCPMC7076283

OpenAlexW3012749233

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.